Xoma Royalty Corp (XOMAP) — SEC Filings
Xoma Royalty Corp (XOMAP) — 41 SEC filings. Latest: 8-K (Dec 5, 2025). Includes 27 8-K, 6 10-Q, 2 10-K.
View Xoma Royalty Corp on SEC EDGAR
Overview
Xoma Royalty Corp (XOMAP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: On December 5, 2025, XOMA Royalty Corp. filed an 8-K report detailing the completion of an acquisition or disposition of assets. The filing also includes other events and financial statements and exhibits. XOMA Royalty Corp. is incorporated in Nevada and its fiscal year ends on December 31.
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 2 bullish, 39 neutral. The dominant filing sentiment for Xoma Royalty Corp is neutral.
Filing Type Overview
Xoma Royalty Corp (XOMAP) has filed 27 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 2 8-K/A, 1 DEFA14A, 1 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of XOMAP's 37 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $38.392M |
| Net Income | $25.609M |
| EPS | N/A |
| Debt-to-Equity | 0.61 |
| Cash Position | $45.189M |
| Operating Margin | N/A |
| Total Assets | $263.151M |
| Total Debt | $108.727M |
Key Executives
- Abigail P. Johnson
Industry Context
XOMA operates in the specialized niche of acquiring royalty and commercial payment receivables, primarily within the pharmaceutical and biotechnology sectors. This industry is characterized by long product development cycles, significant R&D investment, and reliance on intellectual property. Key trends include consolidation among pharmaceutical companies, increasing focus on externalizing non-core assets, and evolving reimbursement and pricing pressures.
Top Tags
financials (5) · corporate-governance (5) · financial-reporting (5) · preferred-stock (5) · acquisition (4) · corporate-action (4) · filing (4) · amendment (4) · financial-statements (4) · disposition (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $25.609M | Swung from a $9.853M loss in 2024 to a profit in 2025, indicating a significant financial turnaround. |
| Total Income and Revenues | $38.392M | Increased by 94% from $19.773M in 2024, driven by strong royalty stream performance. |
| Income from EIR method receivables | $19.039M | Increased from $9.985M in 2024, showing growth in core royalty assets. |
| Income from cost recovery method receivables | $9.125M | Increased from $1.910M in 2024, reflecting successful recovery on certain royalty assets. |
| Gains on Acquisitions | $18.004M | A key contributor to profitability in 2025, demonstrating successful strategic asset integration. |
| Credit Losses on Purchased Receivables (2024) | $23.000M | Absence of these losses in 2025 significantly reduced operating expenses, highlighting improved asset quality or management. |
| Cash and Cash Equivalents | $45.189M | Decreased from $101.654M at year-end 2024, indicating significant cash utilization, likely for acquisitions or operations. |
| Total Assets | $263.151M | Increased from $221.277M at year-end 2024, reflecting growth in the company's asset base, including intangible assets. |
| Long-term Debt | $94.382M | Decreased from $106.875M at year-end 2024, showing a reduction in long-term financial obligations. |
| Common Stock Shares Outstanding | 12,383,103 | As of November 7, 2025, indicating the current dilution level for common stockholders. |
| Report Date | 20251003 | Indicates the date of the filing and the earliest event reported. |
| Fiscal Year End | 1231 | Indicates the end of the company's financial reporting year. |
| SEC File Number | 001-39801 | Unique identifier for the company's SEC filings. |
| Total income and revenues | $29.041M | Increased by 130.9% from $12.576 million for the six months ended June 30, 2024 |
| Net income | $11.558M | Increased from $7.390 million for the six months ended June 30, 2024 |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, passive stake in XOMA Corp.","entity":"FMR LLC","targetDate":"Next 12-18 months","confidence":"high"}
- {"claim":"XOMA Corp's stock price will not be significantly impacted by this passive filing alone.","entity":"XOMA Corp","targetDate":"Next 3 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Xoma Royalty Corp (XOMAP)?
Xoma Royalty Corp has 41 recent SEC filings from Jan 2024 to Dec 2025, including 27 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XOMAP filings?
Across 41 filings, the sentiment breakdown is: 2 bullish, 39 neutral. The dominant sentiment is neutral.
Where can I find Xoma Royalty Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xoma Royalty Corp (XOMAP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xoma Royalty Corp?
Key financial highlights from Xoma Royalty Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XOMAP?
The investment thesis for XOMAP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xoma Royalty Corp?
Key executives identified across Xoma Royalty Corp's filings include Abigail P. Johnson.
What are the main risk factors for Xoma Royalty Corp stock?
Of XOMAP's 37 assessed filings, 0 were flagged high-risk, 16 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Xoma Royalty Corp?
Recent forward-looking statements from Xoma Royalty Corp include guidance on {"claim":"FMR LLC will maintain a significant, passive stake in XOMA Corp.","entity":"FMR LLC","targetDate":"Next 12-18 and 1 other predictions.